Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy
- 1 August 2005
- journal article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 303 (1-2), 81-91
- https://doi.org/10.1016/j.jim.2005.06.008
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- In vitro assays for the diagnosis of IgE-mediated disordersJournal of Allergy and Clinical Immunology, 2004
- Omalizumab: A Novel Therapy for Allergic AsthmaAnnals of Pharmacotherapy, 2004
- Immunotherapy: 1999-2004Journal of Allergy and Clinical Immunology, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical and Experimental Allergy, 2004
- Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils☆Journal of Allergy and Clinical Immunology, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★Journal of Allergy and Clinical Immunology, 1997
- IgE hidden in immune complexes with anti-IgE autoantibodies in children with asthmaJournal of Allergy and Clinical Immunology, 1991
- Allergic RhinitisNew England Journal of Medicine, 1991
- Monoclonal Antibodies Specific for Human IgE-Producing B Cells: A Potential Therapeutic for IgE-Mediated Allergic DiseasesNature Biotechnology, 1990